For instance, A20 was identified as a key target to downregulate the pro-inflammatory NF-kB pathway, and the connectivity mapping approach predicted ikarugamycin and quercetin, FDA-approved drugs with anti-inflammatory effects, to induce A20 expression and therefore reduce the inflammatory response in cystic fibrosis [55]. The gene discussed is NFKB1; the disease is cystic fibrosis.